Cortexyme Inc. Stock News

The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana

Cortexyme (CRTX) provided a business update and announced key milestones for 2022

Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB,

The FDA''s latest move regarding one of this biopharma''s investigational drugs all but slams the door shut on its future.

Cortexyme Inc  (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug f

The FDA has placed a clinical hold on Cortexyme Inc''s (NASDAQ: CRTX ) atuzaginstat (COR388) Investigational New Drug application (IND 134303). The Company plans to provide additional updates pending continued engagement with FDA. Cortexyme is immediately implementing a cost reduction program to rationalize operations, providing an expected cash runway through Full story available on Benzinga.com

Cortexyme (CRTX) drops 33.9% premarket after receiving a letter from the FDA, stating the the Agency is placing a full clinical hold on company''s atuzaginstats (COR388)

Mainz Biomed MYNZ -23% after secures $22.5M capital raiseCortexyme (CRTX) -21% after announces clinical hold on Atuzaginstat’s IND application.Aptorum Group (APM) -7%

The Company plans to provide additional updates pending continued engagement with FDA.

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

A key clinical setback sent investors to the exits last year.

In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on

Cortexyme Inc. (NASDAQ:CRTX) traded at $12.81 at close of the session on Tuesday, 12/21/21, made an upward move of 2.81% on its previous days price. Looking at the stock we see that its previous close was $12.46 and the beta (5Y monthly) reads 0.75 with the days price range being $12.19 $13.179. In terms Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock. Read More »

Cedar Brook Financial Partners LLC purchased a new stake in shares of Cortexyme, Inc. (NASDAQ:CRTX) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 2,218 shares of the biopharmaceutical companys stock, valued at approximately $203,000. Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Ameritas []

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec.